Avdoralimab
- Generic Name
- Avdoralimab
- Drug Type
- Biotech
- CAS Number
- 2226393-85-5
- Unique Ingredient Identifier
- DW4CE8MKS9
- Background
Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Target Recruit Count
- 15
- Registration Number
- NCT04563923
- Locations
- 🇫🇷
CHU de Nice- Dermatologie, Nice, Alpes-Maritimes, France
🇫🇷APHM, Timone, Marseille, Bouche Du Rhône, France
🇫🇷APHM, Hôpital Nord, Marseille, Bouches Du Rhône, France
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection
Phase 2
Completed
- Conditions
- SARS-CoV-2 (COVID-19) InfectionAdvanced or Metastatic Hematological or Solid Tumor
- Interventions
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 19
- Registration Number
- NCT04333914
- Locations
- 🇫🇷
AP-HP Hôpital Bichat Claude Bernard, Paris, France
🇫🇷GH Diaconesses Croix Saint Simon, Paris, France
🇫🇷Institut Gustave Roussy, Villejuif, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath